Studies on muscarinic binding sites in human brain identified with [3H]pirenzepine - PubMed (original) (raw)
Studies on muscarinic binding sites in human brain identified with [3H]pirenzepine
S C Lin et al. J Neurochem. 1986 Jan.
Abstract
Pirenzepine, a potent antimuscarinic agent with apparent selectivity for a subtype (M1) of muscarinic receptors, was used in tritiated form to characterize its binding to human brain tissue. Specific [3H]pirenzepine binding showed rapid association and dissociation. From kinetic and competitive binding experiments, its KD was 5.5 nM and 9 nM, respectively. Regional distribution of [3H]pirenzepine binding determined in parallel with [3H]quinuclidinyl benzilate binding, a nonselective muscarinic antagonist, indicated a significant correlation for the maximum number of binding sites for the two radioligands in 13 brain regions, with the highest amount of binding for each in the putamen and the least in the cerebellum. Binding for [3H]pirenzepine averaged 57% of that for [3H]quinuclidinyl benzilate, with a range of 20% (cerebellum) to 77% (frontal cortex). Most antidepressants and neuroleptics tested had affinities for [3H]pirenzepine binding sites that were not significantly different from their previously reported values obtained with the use of [3H]quinuclidinyl benzilate.
Similar articles
- Multiple binding affinities of N-methylscopolamine to brain muscarinic acetylcholine receptors: differentiation from M1 and M2 receptor subtypes.
el-Fakahany EE, Ramkumar V, Lai WS. el-Fakahany EE, et al. J Pharmacol Exp Ther. 1986 Aug;238(2):554-63. J Pharmacol Exp Ther. 1986. PMID: 3755473 - Regional distribution of M1, M2 and non-M1, non-M2 subtypes of muscarinic binding sites in rat brain.
Ehlert FJ, Tran LP. Ehlert FJ, et al. J Pharmacol Exp Ther. 1990 Dec;255(3):1148-57. J Pharmacol Exp Ther. 1990. PMID: 2262898
Cited by
- Basal forebrain cholinergic system in the dementias: Vulnerability, resilience, and resistance.
Geula C, Dunlop SR, Ayala I, Kawles AS, Flanagan ME, Gefen T, Mesulam MM. Geula C, et al. J Neurochem. 2021 Sep;158(6):1394-1411. doi: 10.1111/jnc.15471. Epub 2021 Aug 6. J Neurochem. 2021. PMID: 34272732 Free PMC article. Review. - Chemical structural novelty: on-targets and off-targets.
Yera ER, Cleves AE, Jain AN. Yera ER, et al. J Med Chem. 2011 Oct 13;54(19):6771-85. doi: 10.1021/jm200666a. Epub 2011 Sep 14. J Med Chem. 2011. PMID: 21916467 Free PMC article. - Brain muscarinic receptors in progressive supranuclear palsy and Parkinson's disease: a positron emission tomographic study.
Asahina M, Suhara T, Shinotoh H, Inoue O, Suzuki K, Hattori T. Asahina M, et al. J Neurol Neurosurg Psychiatry. 1998 Aug;65(2):155-63. doi: 10.1136/jnnp.65.2.155. J Neurol Neurosurg Psychiatry. 1998. PMID: 9703164 Free PMC article. - Chronic administration of Oren-gedoku-to (TJ15) inhibits ischemia-induced changes in brain indoleamine metabolism and muscarinic receptor binding in the Mongolian gerbil.
Kabuto H, Asanuma M, Nishibayashi S, Iida M, Ogawa N. Kabuto H, et al. Neurochem Res. 1997 Jan;22(1):33-6. doi: 10.1023/a:1027369119224. Neurochem Res. 1997. PMID: 9021759 - Effects of 6R-L-erythro-5,6,7,8-tetrahydrobiopterin on the dopaminergic and cholinergic receptors as evaluated by positron emission tomography in the Rhesus monkey.
Tani Y, Ishihara T, Kanai T, Ohno T, Andersson J, Lilja A, Antoni G, Fasth KJ, Bjurling P, Westerberg G, et al. Tani Y, et al. J Neural Transm Gen Sect. 1995;102(3):189-208. doi: 10.1007/BF01281154. J Neural Transm Gen Sect. 1995. PMID: 8788068
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources